



Biosign Reports Results of Annual General Shareholder Meeting

TORONTO, ONTARIO, Tuesday, July 14, 2009 – Biosign Technologies Inc. (CNSX:BIO) (“Biosign”, the “Company”) reports that its shareholders have approved all resolutions brought before them at the Annual General and Special Shareholder Meeting (“AGM”) held on July 10, 2009. Forty-seven percent of the outstanding shares were represented at the meeting.

The Board of Directors was reduced from five to four members, of which three are non-executive and independent directors: Tony LaVista, Senior Account Manager, Royal Bank of Canada (retired), David Silver, Senior Scientist at Johns Hopkins Applied Physics Laboratory, and Terence Young, entrepreneur. The fourth elected director is Radu Leca, the Company’s president.

Shareholder approval was received to re-appoint Cookson Walker LLP as auditor of the Corporation for the ensuing year and to authorize the directors to fix their remuneration. Further, shareholder approval was received to authorize the independent Directors to issue up to twenty-five percent of the share capital to finance the acquisition of strategic technologies and to consolidate the Company's share capital on a one new for up to six old basis. These approvals enable the Board to act promptly, according to needs, as the Company strives to realize its great commercial potential despite the current economic uncertainties. The Board of Directors was also authorized to change the name of the Company, if needed.

The Chairman of the Board, David Silver, provided opening and closing remarks. Biosign’s President and Chief Executive Officer, Radu Leca, spoke to the shareholders and employees about the company’s accomplishments and immediate prospects.

Details will be included in the Company’s monthly report for July 2009.

ON BEHALF OF THE BOARD OF DIRECTORS

Radu Leca, President & CEO

Contact:
Radu Leca, President & CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 222
Email: ceo@biosign.com

About Biosign Technologies Inc.

Biosign provides technologies, products and initiatives to address critical problems in global health care. The focus is on monitoring health status, outcomes, and risk toward maximizing clinical awareness, readiness, and effectiveness. The thrust is on enabling autonomous medical care to optimize healthcare quality, access, and cost. The core technology expands virtual instrumentation with universal measurement and rapid knowledge formation to support service oriented enterprising across global markets. Trademarked UFIT, the web-based technology powers several business lines in self-care, wellness, remote patient monitoring, and chronic disease evaluation and management. Key applications include intelligent systems for noninvasive monitoring of common health risks such as high blood pressure, high blood glucose, and adverse responses to medication. For more information on Biosign please visit <http://www.biosign.com>

The CNSX has neither approved nor disapproved the contents of this press release.

*THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES*

Certain information regarding the Company including management's assessment of future plans and operations, may constitute forward-looking statements under applicable securities laws and necessarily involve risks associated with medical technology companies, research and development, volatility of prices, currency fluctuations, imprecision of estimates, business environment risks, access to labor and services, competition from other companies and ability to access sufficient capital. As a consequence, actual results may differ materially from those anticipated in any forward-looking statements. The Canadian National Stock Exchange (CNSX) does not accept responsibility for the adequacy or accuracy of this release.